| |
Fig. 2. lmx1b MO1 and MO2 prevent full size glomus formation. (A) lmx1b MO1 (panels b, e) or MO2 (panels h and k) was injected into the V2 blastomere at the 8-cell stage. All injections were carried out using a lineage tracer, either GFP (panels a–f) or LacZ (panels g–l). The size of the glomus was assessed by wt1 in situ hybridisation at stage 35/36. Injection of cMO does not induce any phenotype on the injected side (compare panels a to d and g to j). lmx1b MO1 injected embryos (5 ng) showed a reduced glomus (compare panel b to e). A similar phenotype was observed following the injection of lmx1b MO2 (10 ng) (compare panels h to k). Injection of lmx1b-mut mRNA (2.5 ng) can partially rescue the phenotype of MO1 (panels c and f) and MO2 (panels i and l). The injected side is marked with an asterisk. (B) lmx1b MO1 (panels b, e) or MO2 (panels h and k) was injected into one cell of 2-cell embryos. All injections were done using a lineage tracer, either GFP (panels a–f) or LacZ (panels g–l). The size of the glomus was assessed by nephrin in situ hybridisation at stage 33/34. Injection of cMO does not induce any phenotype on the injected side (compare panels a to d and g to j). lmx1b MO1 injected embryos (5 ng) showed a reduced nephrin-staining area on the injected side (compare panels b to e). A similar phenotype was observed following the injection of lmx1b MO2 (10 ng) (compare panels h to k). Injection of lmx1b-mut mRNA (2.5 ng) can partially rescue the phenotype of MO1 (panels c and f) and MO2 (panels i and l). The injected side is marked with an asterisk. |
